Pathogenesis of amyotrophic lateral sclerosis: A critical review

Current Opinion in Neurology

Volumn 12, Issue 5, 1999, Pages 581-588

  Bromberg, Mark B ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE; LYSINE ACETYLSALICYLATE;

AMYOTROPHIC LATERAL SCLEROSIS; DEGENERATIVE DISEASE; HUMAN; PATHOGENESIS; RESPIRATORY FAILURE; REVIEW;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MOTOR NEURONS; SEX CHARACTERISTICS;

EID: 0033394926     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199910000-00012     Document Type: Review

References (47)

1. 1 Rosen D, Siddique T, Patterson D, Figlewicz D, Sapp P, Hentati A, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362:59-62.
2. 2 Morrison B, Morrison J. Amyotrophic lateral sclerosis with mutations in superoxide dismutase: a putative mechanism of degeneration. Brain Res Rev 1999; 29:121-135. This is a review of data from transgenic SOD I mice on the steps in the putative cascade that leads to neuronal death.
3. 3 Enterzari-Taher M, Eisen A, Stewart H, Nakajima M. Abnormalities of cortical inhibitory neurons in amyotrophic lateral sclerosis. Muscle Nerve 1997; 20:65-71.
4. 4 Weber M, Eisen A. Assessment of upperand lower motor neurons in Kennedy's disease: implications for corticomotoneuronal PSTH studies. Muscle Nerve 1999; 22:299-306. This report contrasts abnormalities in upper motor neuron synaptic connections to lower motor neurons in individuals with ALS and Kennedy's disease, and supports a supraspinal pathologic mechanism in ALS.
5. 5 World Federation of Neurology Research Group on Neuromuscular Diseases. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1994; 124 (Suppl):96-107.
6. 6 Ross M, Miller R, Berchert L, Parry G, Barohn R, Armon C, et al. Toward earlier diagnosis of amyotrophic lateral sclerosis. Revised criteria. Neurology 1998; 50:768-772.
7. 7 Cudkowicz M, McKenna-Yasek D, Chen C, Hedley-Whyte E, Brown R. Limited corticospinal tract involvement in amyotrophic lateral sclerosis subjects with the A4V mutation in the copper/zinc superoxide dismutase gene. Ann Neurol 1998; 43:703-710. In families with the A4V SOD I mutation, not all affected members have upper motor neuron loss. This may require a revision of the clinical definition of ALS to make it more general.
8. 8 Andersen P, Forsgren L, Binzer M, Nilsson P, Ala-Hurula V, Keränen M-L, et al. Autosomal recessive adult-onset amyotrophic lateral sclerosis associated with homozygosity for Asp90Ala CuZn-superoxide dismutase mutation. A clinical and genealogical study of 36 patients. Brain 1996; 119: 1153-1172.
9. 9 Al-Chalabi A, Andersen P, Chioza B, Shaw C, Sham P, Robberecht W, et al. Recessive amyotrophic lateral sclerosis families with the D90A SOD1 mutation share a common founder: evidence for a linked protective factor. Hum Mol Genet 1998; 13:2045-2050. Most SOD I mutations are autosomal dominant. The D90A mutation is an exception, and this report confirms that the D90A mutation can act in a dominant manner, but on one occasion it became recessive. They propose a tightly linked protective factor that reduces toxicity. More information about the protective factor could provide new insights into the mechanisms of SOD I pathology.
10. 10 Miller R, Anderson F, Bradley W, Bromberg M, Brooks B, Mitsumoto H, et al. The ALS Patient Care Database: goals, design, and early results. Neurology 1999 (in press).
11. 11 Cashman N, White C, Anderson F, Group ACS. Gender and presentation age in the ALS Patient Care Database [abstract]. Neurology 1999; 52:A116. Although only in abstract form, it represents an epidemiologic approach to investigating the pathogenesis of ALS. A greater incidence of ALS in older, presumably postmenopausal women suggests a protective effect of estrogen in premenopausal women.
12. 12 Kong J, Xu Z. Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expression a mutant SOD1. J Neurosci 1998; 18:3241-3250. By following mutant SOD I transgenic mice according to the stage of the disease and not age of the mice, mitochondrial degeneration was an early change. These data open abnormal energy as a pathogenic factor.
13. 13 Rothstein J. Excitotoxicity hypothesis. Neurology 1996; 47 (Suppl 2):S19-S26.
14. 14 Lin C-LG, Bristol L, Jin L, Dykes-Hoberg M, Crawford T, Clawson L, et al. Aberrant RNA processing in a neurodegenerative disease: the cause of absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron 1998; 20:589-602.
15. 15 Aoki M, Lin C, Rothstein J, Geller B, Hosler B, Munsat T, et al. Mutations in the glutamate transporter EAAT2 gene do not cause abnormal EAAT2 transcripts in amyotrophic lateral sclerosis. Ann Neurol 1998; 43:645-653. Mutations in the EAAT2 gene are unlikely to account for the presence of variant messenger RNA transcripts observed in 60% of sporadic ALS patients.
16. 16 Vogels O, Oyen W, van Engelen B, Padberg G, Horsink M. Decreased striatal dopamine-receptor binding in sporadic ALS: glutamate hyperactivity? Neurology 1999; 52:1275-1277.
17. 17 Krieger C, Jones K, Kim S, Eisen A. The role of intracellular free calcium in motor neuron disease. J Neurol Sci 1994; 124 (Suppl) :27-31.
18. 18 Roy J, Minotti S, Dong L, Figlewicz D, Durham H. Glutamate potentiates the toxicity of mutant Cu/Zu-superoxide dismutase in motor neurons by post-synaptic calcium-dependent mechanisms. J Neurosci 1998; 18:9673-9684. Data from a mutant SOD I cell culture model showing calcium influx through non-NMDA receptors and to a lesser degree through calcium channels.
19. 19 Alexianu M, Ho B-K, Mohamed A, La Bella V, Smith R, Appel S. The role of calcium-binding proteins in selective motorneruon vulnerability in amyotrophic lateral sclerosis. Ann Neurol 1994; 36:846-858.
20. 20 Migheli A, Cordera S, Bendotti C, Atzori C, Piva R, Schiffer D. S-100β is up regulated in astrocytes and motor neurons in the spinal cord of patients with amyotrophic lateral sclerosis. Neurosci Lett 1999; 261 :25-28. This report describes upregulation of a calcium binding protein in astrocytes and neurons in postmortem ALS spinal cords compared with non-neurologic control individuals. Upregulation could represent a possible defense mechanism to neuronal injury.
21. 21 Liu R, Althaus J, Ellerbrock B, Becker D, Gurney M. Enhanced oxygen radical production in a transgenic mouse model of familial amyotrophic lateral sclerosis. Ann Neurol 1998; 44:763-770.
22. 22 Cassarino D, Bennett J. An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration. Brain Res Rev 1999; 29:1-25. This is a review of data on the role of mitochondria in neurodegenerative disorders, including ALS.
23. 23 Wong P, Pardo C, Borchelt D, Lee M, Copeland N, Jenkins N, et al. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 1995; 14:1105-1116.
24. 24 Beal M, Ferrante R, Browne S, Matthews R, Kowall N, Brown R. Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann Neurol 1997; 42:646-654.
25. 25 Phul R, Smith M, Shaw P, Ince P. Expression of nitric oxide synthase in the spinal cord in amyotrophic lateral sclerosis. J Neurol Sci 1998; 160 (Suppl. 1):S87-S91.
26. 26 Strong M, Sopper M, Crow J, Strang W, Beckman J. Nitration of the low molecular weight neurofilament is equivalent in sporadic amyotrophic lateral sclerosis and control cervical spinal cord. Biochem Biophys Res Commun 1998; 248: 157-164. This is a study of postmortem spinal cord tissue from sporadic ALS and non-ALS individuals in which no differences were found in nitration of small neurofilament subunits. This is evidence against nitration as a major pathophysiologic mechanism.
27. 27 Upton-Rice M, Cudkowicz M, Mathew R, Reif D, Brown R. Administration of nitric oxide synthase inhibitors does not alter disease course of amyotrophic lateral sclerosis SOD1 mutant transgenic mice. Ann Neurol 1999; 45:413-414.
28. 28 Urushitani M, Shimohama S, Kihara T, Sawada H, Akaike A, Ibi M, et al. Mechanism of selective motor neuronal death after exposure of spinal cord to glutamate: involvement of glutamate-induced nitric oxide in motor neuron toxicity and nonmotor neuron protection. Ann Neurol 1998; 44:796-807.
29. 29 Beal M. Reply. Ann Neurol 1999; 45:414.
30. 30 Julien J-P, Couillard-Després, Meler J. Transgenic mice in the study of ALS: the role of neurofilaments. Brain Pathol 1998; 8:759-769. This is a review of data on neurofilaments in transgenic SOD I mouse models.
31. 31 Al-Chalabi A, Andersen P, Nilsson P, Chioza B, Andersson J, Russ C, et al. Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis. Hum Mol Genet 1999; 8: 157-64. Genetic abnormalities beyond SOD I mutations have been challenging. Al-Chalabi et al. described finding four mutations in the heavy neurofilament subunit in both sporadic and familial patients and control individuals. Interestingly, motor neuron disease was present only when the mutant allele was paired with the normal allele coding for the longer of the heavy subunits. Although these mutations are rare, they open the door to pathogenetic mechanisms involving this portion of neurofilaments.
32. 32 Williamson T, Bruijn L, Zhu Q, Anderson K, Anderson S, Julien J, et al. Absence of neurofilaments reduces the selective vulnerability of motor neurons and slows disease caused by a familial amyotrophic lateral sclerosis-linked superoxide dismutase 1 mutant. Proc Natl Acad Sci USA 1998; 95:9631-9636. SOD I transgenic mice that also have a disrupted neurofilament light chain gene and hence do not assemble neurofilaments were shown to live longer that SOD I mutant mice with normal neurofilaments. This indicates that neurofilaments are not essential for SOD I-mediated disease.
33. 33 Couillard-Després S, Zhu Q, Wong P, Price D, Cleveland D, Julien J. Protective effect of neurofilament heavy gene overexpression in motor neuron disease induced by mutant superoxide dismutase. Proc Natl Acad Sci USA 1998; 95:9626-9630. Overexpression of the heavy neurofilament subunit in transgenic SOD I mice is protective.
34. 34 Williamson T, Cleveland D. Slowing of axonal transport is a very early event in the toxicity of ALS-linked SOD1 mutants to motor neurons. Nature Neurosci 1999; 2:50-56. Rates of axonal transport, especially tubulin, is slow, and maybe herald early changes in SOD I mutant mice.
35. 35 Chou S, Wang H, Taniguchi A, Bucala R. Advanced glycation endproducts in neurofilament conglomeration of motorneurons in familial and sporadic amytorphic lateral sclerosis. Mol Med 1998; 4:324-332.
36. 36 Bruening W, Roy J, Giasson B, Figlewicz D, Mushynski W, Durham H. Up-regulation of protein chaperones preserves viability of cells expressing toxic Cu/Zn superoxide dismutase mutants associated with amyotrophic lateral sclerosis. J Neurochem 1999; 72:693-699.
37. 37 Rothstein J, Dykes-Hoberg M, Corson L, Becker M, Cleveland D, Price D, et al. The copper chaperone CCS is abundant in neurons and astrocytes in human and rodent brain. J Neurochem 1999; 72:422-429. A copper chaperone protein specific for SOD I enzyme in rat and human central nervous system colocalizes in neurons that degenerate in ALS. These data open a new pathologic pathway for ALS.
38. 38 Casareno R, Waggoner D, Gitlin J. The copper chaperone CCS directly interacts with Copper/Zinc superoxide dismutase. J Biol Chem 1998; 273:23625-23628. Report of specific interactions between a specific copper chaperone protein and both wild-type and a common SOD I mutation. These data open a new pathologic pathway for ALS.
39. 39 Corson L, Strain J, Culotta V, Cleveland D. Chaperone-facilitated copper binding is a property common to several classes of familial amyotrophic lateral sclerosis-linked superoxide dismutase mutants. Proc Natl Acad Sci USA 1998; 95:6361-6366.
40. 40 Pasinelli P, Borchelt D, Housewert M, Cleveland D, Brown R. Caspase-1 is activated in neural cells and tissue with amyotrophic lateral sclerosis-associated mutations in copper-zinc superoxide dismutase. Proc Natl Acad Sci USA 1998; 95: 15763-15768.
41. 41 Martin L. Neuronal death in amyotrophic lateral sclerosis is apoptosis: possible contribution of a programmed cell death mechanism. J Neuropathol Exp Neurol 1999;58:459-471. This is the first clear report from ALS postmortem spinal cord that supports apoptotic cell death in ALS.
42. 42 Klivenyi P, Ferrante R, Matthews R, Bogdanov M, Klein A, Andreassen O, et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nature Med 1999; 5:347-350. This report raised interest among ALS patients for a simple and available treatment for the disease. However, this is a preliminary report that raises interesting questions, but needs to be replicated.
43. 43 Gurney M, Cutting F, Zhai P, Doble A, Taylor C, Andrus P, et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996; 39: 147-157.
44. 44 Tarnopolsky M, Martin J. Creatine monohydrate increases strength in patients with neuromuscular disease. Neurology 1999; 52:854-857.
45. 45 Barnéoud P, Curet O. Beneficial effects of lysine acetylsalicylate, a soluble salt of aspirin, on motor performance in a transgenic model of amyotrophic lateral sclerosis. Exp Neurol 1999; 155:243-251.
46. 46 Wong P, Rothstein J, Price D. The genetic and molecular mechanisms of motor neuron disease. Curr Opin Neurobiol 1998; 8:791-799. This is a review of genetic aspects of ALS, including mutant SOD I transgenic mice, and spinal muscular atrophy. It also includes a review of excitotoxicity and the role of copper.
47. 47 Morrison B, Morrison J, Gordon J. Superoxide dismutase and neurofilament transgenic models of amyotrophic lateral sclerosis. J Exp Zool 1998; 28:32-47. This is a review of data on neurofilaments in transgenic SOD I mouse models.